Amarin Corporation PLC (NASDAQ:AMRN) – Analysts at SunTrust Banks upped their FY2018 EPS estimates for Amarin Corporation PLC in a research note issued on Monday. SunTrust Banks analyst J. Boris now anticipates that the biopharmaceutical company will post earnings per share of ($0.10) for the year, up from their prior forecast of ($0.11). SunTrust Banks also issued estimates for Amarin Corporation PLC’s FY2019 earnings at $0.17 EPS.
Amarin Corporation PLC (NASDAQ:AMRN) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.01. The business had revenue of $44.95 million for the quarter, compared to analysts’ expectations of $40.35 million. During the same quarter in the previous year, the firm earned ($0.07) EPS. Amarin Corporation PLC’s revenue was up 37.0% compared to the same quarter last year. ILLEGAL ACTIVITY NOTICE: “Equities Analysts Offer Predictions for Amarin Corporation PLC’s FY2018 Earnings (AMRN)” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://ledgergazette.com/2017/09/29/equities-analysts-offer-predictions-for-amarin-corporation-plcs-fy2018-earnings-amrn.html.
Other equities research analysts have also recently issued research reports about the company. Jefferies Group LLC reissued a “buy” rating and set a $7.00 target price on shares of Amarin Corporation PLC in a research note on Thursday, August 3rd. BidaskClub lowered Amarin Corporation PLC from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Zacks Investment Research upgraded Amarin Corporation PLC from a “hold” rating to a “buy” rating and set a $4.75 target price for the company in a report on Tuesday, July 11th. Cantor Fitzgerald set a $5.00 target price on Amarin Corporation PLC and gave the company a “buy” rating in a report on Monday, June 12th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a report on Thursday, June 1st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Amarin Corporation PLC has an average rating of “Hold” and an average target price of $7.35.
Amarin Corporation PLC (NASDAQ:AMRN) traded up 0.86% during trading on Thursday, reaching $3.53. The company had a trading volume of 495,062 shares. The company’s 50-day moving average is $3.25 and its 200 day moving average is $3.30. Amarin Corporation PLC has a 52 week low of $2.65 and a 52 week high of $4.47. The firm’s market capitalization is $955.90 million.
In other Amarin Corporation PLC news, General Counsel Joseph T. Kennedy sold 307,911 shares of the business’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $4.00, for a total transaction of $1,231,644.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 3.72% of the company’s stock.
A number of hedge funds have recently bought and sold shares of AMRN. Wells Fargo & Company MN boosted its position in Amarin Corporation PLC by 4.8% in the 1st quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 1,500 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Amarin Corporation PLC by 27.1% in the first quarter. JPMorgan Chase & Co. now owns 35,590 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 7,580 shares during the period. Westside Investment Management Inc. increased its stake in shares of Amarin Corporation PLC by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after purchasing an additional 300 shares during the period. Private Advisor Group LLC increased its stake in shares of Amarin Corporation PLC by 2.1% in the first quarter. Private Advisor Group LLC now owns 50,170 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 1,032 shares during the period. Finally, Perkins Capital Management Inc. increased its stake in shares of Amarin Corporation PLC by 20.3% in the second quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 7,000 shares during the period. 37.76% of the stock is currently owned by hedge funds and other institutional investors.
About Amarin Corporation PLC
Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.
Receive News & Ratings for Amarin Corporation PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amarin Corporation PLC and related companies with MarketBeat.com’s FREE daily email newsletter.